Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04404881 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab In Hereditary Hemorrhagic Telangiectasia
A Phase 2 study of Hereditary Hemorrhagic Telangiectasia, sponsored by Hanny Al-Samkari, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT04404881 is a Phase 2 study of Hereditary Hemorrhagic Telangiectasia that is active but no longer recruiting, run by Hanny Al-Samkari, MD. The registered enrollment target is 33 participants, below the 1,786-participant average among 7 other Hereditary Hemorrhagic Telangiectasia trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04404881, a Phase 2 study of Hereditary Hemorrhagic Telangiectasia, is active but no longer recruiting, sponsored by Hanny Al-Samkari, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying to see whether bevacizumab may treat chronic bleeding and iron deficiency anemia in Hereditary Hemorrhagic Telangiectasia (HHT). Hereditary Hemorrhagic Telangiectasia (HHT) is a disorder that causes abnormal blood vessel formation. In HHT, there is a mutation in the TGF-β pathway, which results in an increase of vascular endothelial growth factor (VEGF) levels. An increase in VEGF levels can result in poorly formed blood vessels that have a higher rate of bleeding than normal blood vessels. Bevacizumab is designed to block VEGF activity. It is believed that targeting increased VEGF levels may be able to treat HHT. This research study involves the following study drug: \- Bevacizumab
Conditions Studied
Interventions
- DRUG Bevacizumab (Avastin®)
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2020-11-23 |
| Est. Completion | 2027-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04404881
The ClinicalTrials.gov registry entry for NCT04404881 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,786-participant average among 7 other Hereditary Hemorrhagic Telangiectasia trials with a reported enrollment target (98% lower). The listed sponsor is Hanny Al-Samkari, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hereditary Hemorrhagic Telangiectasia appearing as the primary indexed condition, and to 1 intervention - of which Bevacizumab (Avastin®) is the first listed.
NCT04404881 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04404881 about?
NCT04404881 is a clinical study titled "Bevacizumab In Hereditary Hemorrhagic Telangiectasia". This research study is studying to see whether bevacizumab may treat chronic bleeding and iron deficiency anemia in Hereditary Hemorrhagic Telangiectasia (HHT). Hereditary Hemorrhagic Telangiectasia (HHT) is a disorder that causes abnormal blood vessel formation. In HHT, there is a mutation in the ...
What is the current status of trial NCT04404881?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2020-11-23. Estimated completion is 2027-02-01.
What conditions does trial NCT04404881 study?
This clinical trial studies the following conditions: Hereditary Hemorrhagic Telangiectasia.
What interventions are being tested in trial NCT04404881?
The interventions under investigation include: Bevacizumab (Avastin®) (DRUG).
Who is sponsoring clinical trial NCT04404881?
This trial is sponsored by Hanny Al-Samkari, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04404881 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Hemorrhagic Telangiectasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
ACTIVE NOT RECRUITING · Phase 2
-
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
RECRUITING
-
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
RECRUITING · Phase 1
-
Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia
ACTIVE NOT RECRUITING
-
Ultra-low-dose Chest CT for HHT
ACTIVE NOT RECRUITING
-
Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.